Subchondral stem cell therapy versus contralateral total knee arthroplasty for osteoarthritis following secondary osteonecrosis of the knee

  • Philippe Hernigou
  • Jean Charles Auregan
  • Arnaud Dubory
  • Charles Henri Flouzat-Lachaniette
  • Nathalie Chevallier
  • Helene Rouard
Original Paper

Abstract

Purpose

Total knee arthroplasty (TKA) implanted in patients with secondary osteonecrosis (ON) related to corticosteroids have relatively poor outcome (20% revision rate) at a mean follow-up of only eight years. With the hypothesis that subchondral bone marrow injection might improve knees in these patients, we evaluated 30 patients who had bilateral knee osteoarthritis with severe joint space narrowing and received TKA in one knee and subchondral bone marrow concentrate injection in the contralateral knee.

Material and methods

A prospective randomized controlled clinical trial was carried out in 60 knees of 30 patients (mean age 28 years, 18–41) who presented bilateral osteoarthritis secondary to knee ON related to corticosteroids in relation with different severe medical conditions. During the same anesthesia, one knee received TKA; for the other knee, a bone marrow graft containing an average of 6500 MSCs/mL (counted as CFU-F, range 3420 to 9830) was delivered to the subchondral bone of the femur and tibia. The length of anesthesia related to each procedure (bone marrow aspiration and subchondral injection of concentrated bone marrow versus total knee arthroplasty) was measured. Peri-operative outcomes, morbidity, complications, and safety of the two procedures were compared. Subsequent admissions for revision surgery were identified. At the most recent follow-up (average of 12 years, range 8 to 16 years), clinical outcomes of the patient (Knee Society score) were obtained along with radiological imaging outcomes (MRIs for knees with subchondral bone marrow injection).

Results

Anesthesia related to the TKA side was longer than for the cell therapy group. Medical and surgical complications were more frequent after TKA. A higher number of thrombophlebitis was observed on the side with TKA (15%) versus none on the side with cell therapy (0%). At the most recent follow-up (average of 12 years, range 8 to 16 years), six (out of 30) TKA knees needed subsequent surgery versus only one with cell therapy. The Knee Score had improved and remained similar in the TKA and cell therapy groups (respectively 80.3 points ± 11 versus 78.3 ± 23); 21 patients preferred the knee with cell therapy and 9 preferred the knee with TKA. Knees with cell therapy had improvement on cartilage and bone marrow lesions observed at the site of bone marrow subchondral injection.

Conclusions

Subchondral autologous bone marrow concentrate was an effective procedure for treating young patients with knee osteoarthritis following secondary ON of the knee related to corticosteroids with a lower complication rate and a quicker recovery as compared with TKA.

Keywords

Knee osteonecrosis Osteoarthritis Total knee arthroplasty Stem cell therapy Bone marrow injection Mesenchymal stem cell Corticosteroids 

Notes

Acknowledgments

We thank Richard Suzuki and Meghana Malur of Celling Biosciences for the review of the final manuscript and their help in translation.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Myers TG, Cui Q, Kuskowski M, Mihalko WM, Saleh KJ (2006) Outcomes of total and unicompartmental knee arthroplasty for secondary and spontaneous osteonecrosis of the knee. J Bone Joint Surg Am 88(Suppl 3):76–82PubMedGoogle Scholar
  2. 2.
    Mont MA, Myers TH, Krackow KA et al (1997) Total knee arthroplasty for corticosteroid associated avascular necrosis of the knee. Clin Orthop Relat Res 338:124CrossRefGoogle Scholar
  3. 3.
    Seldes RM, Tan V, Duffy G, Rand JA, Lotke PA (1999) Total knee arthroplasty for steroid-induced osteonecrosis. J Arthroplast 14:533–537CrossRefGoogle Scholar
  4. 4.
    Mont MA, Baumgarten KM, Rifai A et al (2000) Atraumatic osteonecrosis of the knee. J Bone Joint Surg Am 82(9):1279CrossRefPubMedGoogle Scholar
  5. 5.
    Vora A (2011) Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia. Br J Haematol 155(5):549CrossRefPubMedGoogle Scholar
  6. 6.
    Mertelsmann-Voss C, Lyman S, Pan TJ et al (2014) Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991-2005. J Rheumatol 41(5):867CrossRefPubMedGoogle Scholar
  7. 7.
    Hernigou P, Poignard A, Beaujean F, Rouard H (2005) Percutaneous autologous bone marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 87:1430–1437PubMedGoogle Scholar
  8. 8.
    Hernigou P, Beaujean F (2002) Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 405:14CrossRefGoogle Scholar
  9. 9.
    Dray A, Read SJ (2007) Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther 9(3):212CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tat SK, Lajeunesse D, Pelletier J-P, Martel-Pelletier J (2010) Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 24(1):51–70PubMedCentralGoogle Scholar
  11. 11.
    Marulanda G, Seyler TM, Sheikh NH et al (2006) Percutaneous drilling for the treatment of secondary osteonecrosis of the knee. J Bone Joint Surg (Br) 88(6):740CrossRefGoogle Scholar
  12. 12.
    Mont MA, Marker DR, Zywiel MG et al (2011) Osteonecrosis of the knee and related conditions. J Am Acad Orthop Surg 19(8):482CrossRefPubMedGoogle Scholar
  13. 13.
    Karimova EJ, Wozniak A, Wu J et al (2010) How does osteonecrosis about the knee progress in young patients with leukemia?: a 2- to 7-year study. Clin Orthop Relat Res 468(9):2454CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shigemura T, Nakamura J, Kishida S et al (2011) Incidence of osteonecrosis associated with corticosteroid therapy among different underlying diseases: prospective MRI study. Rheumatology 50(11):202312CrossRefGoogle Scholar
  15. 15.
    Flouzat-Lachaniette CH, Roubineau F, Heyberger C, Bouthors C, Hernigou P (2016) Multifocal osteonecrosis related to corticosteroid: ten years later, risk of progression and observation of subsequent new osteonecroses. Int Orthop 40(4):669–672CrossRefPubMedGoogle Scholar
  16. 16.
    al-Rowaih A, Bjorkengren A, Egund N, et al. (1993) Size of osteonecrosis of the knee. Clin Orthop Relat Res (287):68Google Scholar
  17. 17.
    Hernigou J, Picard L, Alves A, Silvera J, Homma Y, Hernigou P (2014) Understanding bone safety zones during bone marrow aspiration from the iliac crest: the sector rule. Int Orthop 38(11):2377–2384CrossRefPubMedGoogle Scholar
  18. 18.
    Hernigou J, Alves A, Homma Y, Guissou I, Hernigou P (2014) Anatomy of the ilium for bone marrow aspiration: map of sectors and implication for safe trocar placement. Int Orthop 38(12):2585–2590CrossRefPubMedGoogle Scholar
  19. 19.
    Hernigou P, Homma Y, Flouzat Lachaniette CH, Poignard A, Allain J, Chevallier N, Rouard H (2013) Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells. Int Orthop 37(11):2279–2287CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lebouvier A, Poignard A, Coquelin-Salsac L, Léotot J, Homma Y, Jullien N, Bierling P, Galactéros F, Hernigou P, Chevallier N, Rouard H (2015) Autologous bone marrow stromal cells are promising candidates for cell therapy approaches to treat bone degeneration in sickle cell disease. Stem Cell Res 15(3):584–594CrossRefPubMedGoogle Scholar
  21. 21.
    Insall JN, Dorr LD, Scott RD, Scott WN (1989) Rationale of the Knee Society clinical rating system. Clin Orthop Relat Res 248:13–14Google Scholar
  22. 22.
    Pelletier JP, Raynauld JP, Abram F, Haraoui B, Choquette D, Martel-Pelletier J (2008) A new non-invasive method to assess synovitis severity in relation to symptoms and cartilage volume loss in knee osteoarthritis patients using MRI. Osteoarthr Cartil 16(Suppl 3):S8–S13Google Scholar
  23. 23.
    Roemer FW, Guermazi A, Javaid MK, Lynch JA, Niu J, Zhang Y, Felson DT, Lewis CE, Torner J, Nevitt MC (2009) Change in MRI-detected subchondral bone marrow lesions is associated with cartilage loss—the MOST study a longitudinal multicenter study of knee osteoarthritis. Ann Rheum Dis 68:1461–1465CrossRefPubMedGoogle Scholar
  24. 24.
    Wluka AE, Hanna FS, Davies-Tuck M, Wang Y, Bell RJ, Davis SR, Adams J, Cicuttini FM (2009) Bone marrow lesions predict increase in knee cartilage defects and loss of cartilage volume in middle-aged women without knee pain over 2 years. Ann Rheum Dis 68:850–855CrossRefPubMedGoogle Scholar
  25. 25.
    Hoemann CD, Chen G, Marchand C, Tran-Khanh N, Thibault M, Chevrier A, Sun J, Shive MS, Fernandes MJ, Poubelle PE, Centola M, El-Gabalawy H (2010) Scaffold-guided subchondral bone repair: implication of neutrophils and alternatively activated arginase-1C macrophages. Am J Sports Med 38:1845–1856CrossRefPubMedGoogle Scholar
  26. 26.
    Van der Linden MH, Saris D, Bulstra SK, Buma P (2013) Treatment of cartilaginous defects in the knee: recommendations from the Dutch Orthopaedic Association. Ned Tijdschr Geneeskd 157(3):A5719PubMedGoogle Scholar
  27. 27.
    Hernigou P, Beaujean F, Lambotte JC (1999) Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg (Br) 81(2):349CrossRefGoogle Scholar
  28. 28.
    Felson DT, Niu J, Guermazi A, Roemer F, Aliabadi P, Clancy M, Torner J, Lewis CE, Nevitt MC (2007) Correlation of the development of knee pain with enlarging bone marrow lesions on magnetic resonance imaging. Arthritis Rheum 56:2986–2992CrossRefPubMedGoogle Scholar
  29. 29.
    Lieberman JR, Varthi AG, Polkowski GG II (2014) Osteonecrosis of the knee—which joint preservation procedures work? J Arthroplast 29(1):52CrossRefGoogle Scholar
  30. 30.
    Rijnen WH, Luttjeboer JS, Schreurs BW et al (2006) Bone impaction grafting for corticosteroid-associated osteonecrosis of the knee. J Bone Joint Surg Am 88(Suppl 3):62PubMedGoogle Scholar
  31. 31.
    Gortz S, De Young AJ, Bugbee WD (2010) Fresh osteochondral allografting for steroid-associated osteonecrosis of the femoral condyles. Clin Orthop Relat Res 468(5):1269CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Lee K, Goodman SB (2009) Cell therapy for secondary osteonecrosis of the femoral condyles using the Cellect DBM System: a preliminary report. J Arthroplast 24(1):43CrossRefGoogle Scholar
  33. 33.
    Sultan AA, Khlopas A, Sodhi N, Denzine ML, Ramkumar PN, Harwin SF, Mont MA (2017) Cementless total knee arthroplasty in Knee osteonecrosis demonstrated excellent survivorship and outcomes at three-year minimum follow-up. J Arthroplasty. Nov 8Google Scholar

Copyright information

© SICOT aisbl 2018

Authors and Affiliations

  • Philippe Hernigou
    • 1
  • Jean Charles Auregan
    • 1
  • Arnaud Dubory
    • 1
  • Charles Henri Flouzat-Lachaniette
    • 1
  • Nathalie Chevallier
    • 1
  • Helene Rouard
    • 1
  1. 1.Hôpital Henri MondorCreteilFrance

Personalised recommendations